Alk

ALK, a pharmaceutical preparation manufacturer headquartered in DK, has demonstrated a commitment to reducing its carbon footprint. In 2023, ALK reported total global emissions of approximately 69,555,000 kg CO2e. This figure encompasses Scope 1 emissions totalling about 5,128,000 kg CO2e, with Scope 2 (market-based) at approximately 360,000 kg CO2e and Scope 3 emissions at approximately 64,067,000 kg CO2e. Scope 3 emissions were significantly driven by purchased goods and services, amounting to approximately 41,175,000 kg CO2e.

ALK has set ambitious climate targets, approved by the Science Based Targets initiative (SBTi). The company commits to reducing absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using a 2022 baseline. Furthermore, ALK aims for 80% of its suppliers, by emissions, to have science-based targets by 2028. This supplier engagement covers key categories including purchased goods and services, capital goods, upstream and downstream transportation and distribution, and business travel.

The company's sustainability efforts are reflected in its emission reduction progress. Between 2019 and 2022, ALK reported a reduction of 41% in its Scope 1 and Scope 2 CO2 emissions. The company's latest emissions data for 2025 indicates Scope 1 and 2 emissions of approximately 4,883,000 kg CO2e, a notable decrease from previous years. ALK's sustainability reporting includes a commitment to a long-term net-zero target by 2045, encompassing its entire value chain.